Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

402 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differences in internalized HIV stigma across subpopulations of people with HIV in care across the United States.
Drumright LN, Johnson MO, Mayer KH, Christopoulos K, Cachay E, Crawford TN, Whitney BM, Dai M, Ruderman SA, Mixson LS, Keruly JC, Chander G, Saag MS, Kitahata MM, Moore RD, Willig AL, Eron JJ, Napravnik S, Nance RM, Hahn A, Ma J, Bamford L, Fredericksen RJ, Delaney JAC, Crane HM. Drumright LN, et al. Among authors: saag ms. AIDS. 2024 Jul 1;38(8):1206-1215. doi: 10.1097/QAD.0000000000003864. Epub 2024 Feb 9. AIDS. 2024. PMID: 38349228
The Vancouver Consensus: antiretroviral medicines, medical evidence, and political will.
Beyrer C, Birx DL, Bekker LG, Barré-Sinoussi F, Cahn P, Dybul MR, Eholié SP, Kavanagh MM, Katabira ET, Lundgren JD, Mworeko L, Pala M, Puttanakit T, Ryan O, Sidibé M, Montaner JS; Vancouver Consensus Signatories. Beyrer C, et al. Lancet. 2015 Aug 8;386(9993):505-7. doi: 10.1016/S0140-6736(15)61458-1. Lancet. 2015. PMID: 26293427 No abstract available.
Maraviroc for previously treated patients with R5 HIV-1 infection.
Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H; MOTIVATE Study Teams. Gulick RM, et al. N Engl J Med. 2008 Oct 2;359(14):1429-41. doi: 10.1056/NEJMoa0803152. N Engl J Med. 2008. PMID: 18832244 Free PMC article. Clinical Trial.
High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.
Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, Stancil B, Mosteller M, Brothers C, Wannamaker P, Hughes A, Sutherland-Phillips D, Mallal S, Shaefer M; Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team. Saag M, et al. Clin Infect Dis. 2008 Apr 1;46(7):1111-8. doi: 10.1086/529382. Clin Infect Dis. 2008. PMID: 18444831 Free article.
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S; extended SAILING Study Team. Cahn P, et al. Lancet. 2013 Aug 24;382(9893):700-8. doi: 10.1016/S0140-6736(13)61221-0. Epub 2013 Jul 3. Lancet. 2013. PMID: 23830355 Clinical Trial.
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade-Villanueva J, Workman C, Zajdenverg R, Fätkenheuer G, Berger DS, Kumar PN, Rodgers AJ, Shaughnessy MA, Walker ML, Barnard RJ, Miller MD, Dinubile MJ, Nguyen BY, Leavitt R, Xu X, Sklar P; SWITCHMRK 1 and 2 investigators. Eron JJ, et al. Lancet. 2010 Jan 30;375(9712):396-407. doi: 10.1016/S0140-6736(09)62041-9. Epub 2010 Jan 12. Lancet. 2010. PMID: 20074791 Clinical Trial.
Cumulative HIV viral load and lower CD4 cell count are associated with incident venous thromboembolism in people with HIV.
Ruderman SA, Nance RM, Crane HM, Cachay E, Kitahata MM, Napravnik S, Whitney BM, Heckbert SR, Attia EF, Longenecker CT, Hoffmann AP, Budoff MJ, Ma J, Christopoulos K, Hunt PW, Moore RD, Keruly JC, Burkholder G, Bamford L, Willig AL, Chander G, Saag MS, Drumright LN, Feinstein MJ, Crothers K, Delaney JA. Ruderman SA, et al. Among authors: saag ms. AIDS. 2024 Dec 18. doi: 10.1097/QAD.0000000000004095. Online ahead of print. AIDS. 2024. PMID: 39693493
Correction: Severity and Number of Substances Used are Independently Associated with Antiretroviral Therapy Adherence Over Time Among People with HIV in the Current Treatment Era.
Ma J, Delaney JAC, Ruderman SA, Nance RM, Hahn AW, Drumright LN, Whitney BM, Fredericksen RJ, Mixson LS, Merrill JO, Safren SA, Mayer KH, O'Cleirigh C, Napravnik S, Chander G, Moore RD, Christopoulos KA, Willig AL, Bamford L, Webel A, McCaul ME, Cachay ER, Jacobson JM, Saag MS, Kitahata MM, Crane HM, Williams EC. Ma J, et al. Among authors: saag ms. AIDS Behav. 2024 Dec 3. doi: 10.1007/s10461-024-04566-x. Online ahead of print. AIDS Behav. 2024. PMID: 39625560 No abstract available.
Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel.
Gandhi RT, Landovitz RJ, Sax PE, Smith DM, Springer SA, Günthard HF, Thompson MA, Bedimo RJ, Benson CA, Buchbinder SP, Crabtree-Ramirez BE, Del Rio C, Eaton EF, Eron JJ Jr, Hoy JF, Lehmann C, Molina JM, Jacobsen DM, Saag MS. Gandhi RT, et al. Among authors: saag ms. JAMA. 2024 Dec 1. doi: 10.1001/jama.2024.24543. Online ahead of print. JAMA. 2024. PMID: 39616604
402 results